Back to Search Start Over

Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology

Authors :
Kathryn A Ryan
Katarzyna E Schewe
Jonathan Crowe
Susan A Fotheringham
Yper Hall
Richard Humphreys
Anthony C Marriott
Jemma Paterson
Emma Rayner
Francisco J Salguero
Robert J Watson
Catherine J Whittaker
Miles W Carroll
Oliver Dibben
Source :
The Journal of Infectious Diseases. 225:404-412
Publication Year :
2021
Publisher :
Oxford University Press (OUP), 2021.

Abstract

Cocirculation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in coinfected patients. The initial lack of a readily available coronavirus disease 2019 (COVID-19) vaccine has reinforced the importance of influenza vaccine programs during the COVID-19 pandemic. Live attenuated influenza vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration influences the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV was administered to ferrets 3 days before or after SARS-CoV-2 infection. LAIV administration did not exacerbate the SARS-CoV-2 disease course or lung pathology with either regimen. In addition, LAIV administered before SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract. This study demonstrated that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding.

Details

ISSN :
15376613 and 00221899
Volume :
225
Database :
OpenAIRE
Journal :
The Journal of Infectious Diseases
Accession number :
edsair.doi...........ce29ba68b8706c4b49fad8ae732d41b5